ABSTRACT
Inflammation caused by obesity, especially central obesity, is thought to be the underlying basis of a significant number of diseases including cardiovascular disease, metabolic syndrome, hypertension, diabetes, hyperlipidemia, and cancer [Trayhurn, 2005]. The importance of adipose tissue in such epidemic diseases led pharmaceutical companies to target adipocyte metabolism in their searches for drugs for treating or reducing the risk of these conditions.
